文献速递重症综合管理与镇静镇痛儿科与产科急症

儿童脓毒症中的病毒DNA血症与DNA病毒血清阳性及死亡率

Viral DNAemia and DNA Virus Seropositivity and Mortality in Pediatric Sepsis.
PubMed 文献 · JAMA Netw Open · 2024-02-05
一句话结论在重症脓毒症患儿中,CMV、HAdV、BKPyV和HHV-6 DNA血症及EBV血清阳性与PICU死亡率升高独立相关。

这项多中心队列研究纳入美国9个PICU的401例18岁以下重症脓毒症患儿,检测血浆中CMV、EBV、HSV-1、HHV-6、B19V、BKPyV、HAdV和TTV的DNA以及CMV、EBV、HSV-1、HHV-6的IgG抗体。校正年龄、儿科死亡风险评分、既往健康状态和免疫抑制状态后,CMV(AOR 3.01,95%CI 1.36-6.45;P=0.007)、HAdV(AOR 3.50,95%CI 1.46-8.09;P=0.006)、BKPyV(AOR 3.02,95%CI 1.17-7.34;P=0.02)和HHV-6(AOR 2.62,95%CI 1.31-5.20;P=0.007)DNA血症均与死亡率升高相关。额外校正PICU内接受血制品后,EBV血清阳性与死亡率升高相关(AOR 6.10,95%CI 1.00-118.61;P=0.049)。作者认为,这些病毒DNA感染在脓毒症患儿中的生物学机制值得进一步研究,以确定其仅反映死亡风险还是参与死亡过程。

要点

  • 重症脓毒症患儿中,检出CMV DNA血症与PICU死亡风险升高独立相关(AOR 3.01,95%CI 1.36-6.45;P=0.007)。
  • HAdV DNA血症与PICU死亡风险升高独立相关(AOR 3.50,95%CI 1.46-8.09;P=0.006)。
  • BKPyV DNA血症与死亡风险升高独立相关(AOR 3.02,95%CI 1.17-7.34;P=0.02),HHV-6 DNA血症与死亡风险升高独立相关(AOR 2.62,95%CI 1.31-5.20;P=0.007)。
  • 至少1种病毒(除外TTV)DNA血症见于191/401例(47.6%),免疫抑制患儿为63/108例(58.3%),非免疫抑制患儿为128/293例(43.7%)。
  • 检出2种及以上病毒者78例(19.5%),其中免疫抑制患儿死亡12/32例(37.5%),非免疫抑制患儿死亡9/46例(19.6%)。

适用人群与场景

  • 18岁以下重症脓毒症患儿,来自美国9个PICU,2015至2018年入组。
  • 入组时154例(38.4%)既往健康,108例(26.9%)免疫抑制,225例(56.1%)有明确感染。

研究设计与关键结果

  • 多中心队列研究,401例重症脓毒症患儿,中位年龄6岁(IQR 1-12),男性222例(55.4%)。
  • PICU死亡44例(11.0%)。
  • 校正年龄、儿科死亡风险评分、既往健康状态和免疫抑制状态后,CMV DNA血症与死亡率升高相关(AOR 3.01,95%CI 1.36-6.45;P=0.007),HAdV DNA血症与死亡率升高相关(AOR 3.50,95%CI 1.46-8.09;P=0.006),BKPyV DNA血症与死亡率升高相关(AOR 3.02,95%CI 1.17-7.34;P=0.02),HHV-6 DNA血症与死亡率升高相关(AOR 2.62,95%CI 1.31-5.20;P=0.007)。
  • 额外校正PICU内接受血制品后,EBV血清阳性与死亡率升高相关(AOR 6.10,95%CI 1.00-118.61;P=0.049)。
  • 疱疹病毒血清阳性率:HSV-1 82/246例(33.3%),CMV 107/254例(42.1%),EBV 152/251例(60.6%),HHV-6 253/257例(98.4%)。

证据类型、等级与局限

  • 证据类型:多中心队列研究。
  • 局限:原文未报告局限性;作者指出需进一步研究这些病毒DNA感染在脓毒症患儿中的生物学机制,以确定其仅反映死亡风险还是参与死亡过程。

对床旁实践的改变

  • 作者认为,CMV、HAdV、BKPyV和HHV-6 DNA血症及EBV血清阳性与儿童脓毒症死亡风险升高独立相关。
  • 作者认为,需进一步研究这些病毒DNA感染的生物学机制,以确定其仅反映死亡风险还是参与死亡过程。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Sepsis is a leading cause of pediatric mortality. Little attention has been paid to the association between viral DNA and mortality in children and adolescents with sepsis.

OBJECTIVE: To assess the association of the presence of viral DNA with sepsis-related mortality in a large multicenter study.

DESIGN, SETTING, AND PARTICIPANTS: This cohort study compares pediatric patients with and without plasma cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex virus 1 (HSV-1), human herpesvirus 6 (HHV-6), parvovirus B19 (B19V), BK polyomavirus (BKPyV), human adenovirus (HAdV), and torque teno virus (TTV) DNAemia detected by quantitative real-time polymerase chain reaction or plasma IgG antibodies to CMV, EBV, HSV-1, or HHV-6. A total of 401 patients younger than 18 years with severe sepsis were enrolled from 9 pediatric intensive care units (PICUs) in the Eunice Kennedy Shriver National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network. Data were collected from 2015 to 2018. Samples were assayed from 2019 to 2022. Data were analyzed from 2022 to 2023.

MAIN OUTCOMES AND MEASURES: Death while in the PICU.

RESULTS: Among the 401 patients included in the analysis, the median age was 6 (IQR, 1-12) years, and 222 (55.4%) were male. One hundred fifty-four patients (38.4%) were previously healthy, 108 (26.9%) were immunocompromised, and 225 (56.1%) had documented infection(s) at enrollment. Forty-four patients (11.0%) died in the PICU. Viral DNAemia with at least 1 virus (excluding TTV) was detected in 191 patients (47.6%) overall, 63 of 108 patients (58.3%) who were immunocompromised, and 128 of 293 (43.7%) who were not immunocompromised at sepsis onset. After adjustment for age, Pediatric Risk of Mortality score, previously healthy status, and immunocompromised status at sepsis onset, CMV (adjusted odds ratio [AOR], 3.01 [95% CI, 1.36-6.45]; P = .007), HAdV (AOR, 3.50 [95% CI, 1.46-8.09]; P = .006), BKPyV (AOR. 3.02 [95% CI, 1.17-7.34]; P = .02), and HHV-6 (AOR, 2.62 [95% CI, 1.31-5.20]; P = .007) DNAemia were each associated with increased mortality. Two or more viruses were detected in 78 patients (19.5%), with mortality among 12 of 32 (37.5%) who were immunocompromised and 9 of 46 (19.6%) who were not immunocompromised at sepsis onset. Herpesvirus seropositivity was common (HSV-1, 82 of 246 [33.3%]; CMV, 107 of 254 [42.1%]; EBV, 152 of 251 [60.6%]; HHV-6, 253 if 257 [98.4%]). After additional adjustment for receipt of blood products in the PICU, EBV seropositivity was associated with increased mortality (AOR, 6.10 [95% CI, 1.00-118.61]; P = .049).

CONCLUSIONS AND RELEVANCE: The findings of this cohort study suggest that DNAemia for CMV, HAdV, BKPyV, and HHV-6 and EBV seropositivity were independently associated with increased sepsis mortality. Further investigation of the underlying biology of these viral DNA infections in children with sepsis is warranted to determine whether they only reflect mortality risk or contribute to mortality.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Cabler SS, Storch GA, Weinberg JB, et al. Viral DNAemia and DNA Virus Seropositivity and Mortality in Pediatric Sepsis. JAMA Netw Open. 2024. PMID: 38407904. doi:10.1001/jamanetworkopen.2024.0383

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。